The battle for the acquisition that will form the world's third
biggest generic drugmaker has intensified, with Iceland's Actavis
making a new offer for Croatian drug manufacturer Pliva that
surpasses that of US pharmaceutical...
Reforms do not come cheap, certainly not for Croatian
pharmaceutical company Pliva, whose strategy of abandoning its
proprietary drugs in favour of generics may pay off in the long
term, but, along with manufacturing consolidation...
Croatian drug firm Pliva has sold its Dresden production plant to
Italy's Menarini Group as it tries to recover losses suffered by
its failed venture in proprietor drugs and an end to most of the
royalties it receives.
Croatian pharmaceutical company Pliva has signed a new three-year
agreement with Pfizer for the bulk supply of azithromycin, the
active ingredient in the antibacterial drug Zithromax.
Croatian pharmaceutical company Pliva has decided to opt out of the
proprietary medicines business and refocus its business on the
generics and active pharmaceutical ingredients sectors, reports
Phil Taylor.
Croatian pharmaceutical company Pliva has forged another
partnership in the generic biopharmaceutical sector, linking up
with US firm Barr Laboratories to develop a generic version of
Amgen's white blood cell stimulator Neupogen...
Pliva, the Eastern European giant, is today hosting a R&D day
in London. The company says that it plans to update investors and
analysts alike on the recent developments in the company's R&D
pipeline.
